Abstract:Background: Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer, accounting for the majority of liver cancer cases. Hepatocellular Carcinoma not only exhibits high heterogeneity but also possesses an immune-suppressive tumor microenvironment that promotes tumor evasion, posing substantial difficulties for efficient therapy. Our aim is to utilize single-cell RNA transcriptome data to investigate the dynamic changes in the tumor microenvironment during the malignant progression of HCC, the communication among immune cells, and the marker genes associated with patient prognosis. Methods: We constructed expression matrices from open single-cell RNA transcriptome data (GSE149614) of HCC patients (representing stages I-IV), establishing single-cell RNA transcriptional atlases for different stages of HCC progression. For each stage, we conducted cell subgroup analysis to identify cell types at each stage. Horizontally, we explored the dynamic changes of the same cell type across different stages, performing trajectory analysis and prognosis analysis. Vertically, we investigated pairwise comparisons of different stages of HCC progression, probing the dynamic alterations in tumor microenvironment immune cell signaling pathways. Finally, potential drugs for the treatment of HCC were predicted based on relevant genes. Findings: As the HCC advances towards increased malignancy, there is a shift in the predominant composition of the tumor microenvironment, with a decline in the dominance of hepatic cells. Tumor-infiltrating immune cells migrate and accumulate within the tumor microenvironment, where T cells and myeloid cells display distinct patterns of change. Genes associated with cancer-associated fibroblasts (CAFs) and T cells are correlated with adverse patient outcomes. In the late stages of HCC, the tumor microenvironment is infiltrated by more myeloid-derived suppressor cells (MDSCs), and a prognostic model constructed based on genes related to myeloid cells can predict patient outcomes. Additionally, in the analysis of transcription factors, YY1 and MYC are found to be highly expressed. Cell communication analysis among tumor-infiltrating immune cells reveals significant differences in the main signaling pathways at different stages of HCC progression. Finally, drug sensitivity analysis based on key genes identifies Acetalax, Allopurinol, and Amonafide as potential candidates for HCC treatment.

Comparison of Gene Expression in Hepatocellular Carcinoma, Liver Development, and Liver Regeneration

In Silico Analysis Suggests Disruption of Interactions Between HAMP from Hepatocytes and SLC40A1 from Macrophages in Hepatocellular Carcinoma.

Transcriptional Control: A Directional Sign at the Crossroads of Adult Hepatic Progenitor Cells' Fates

Genes Encoding Pir51, Beclin 1, RbAp48 and Aldolase B Are Up or Down-Regulated in Human Primary Hepatocellular Carcinoma.

Insight into Hepatocellular Carcinogenesis at Transcriptome Level by Comparing Gene Expression Profiles of Hepatocellular Carcinoma with Those of Corresponding Noncancerous Liver

Gene Expression Patterns in Human Liver Cancers

Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma

Gene expression signatures of stepwise progression of Hepatocellular Carcinoma

[Analysis of Differential Gene Expression in Rat Hepatic Stellate Cells Activated by Culture or Hepatocellular Carcinoma Cell Induction].

Expression of cell cycle/growth regulator genes in human hepatocellular carcinoma and adjacent normal liver tissues.

Liver regeneration: Cellular origin and molecular mechanisms

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis

Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma

Comparison of Immune Profiles Between Hepatocellular Carcinoma Subtypes

Systems analysis of key genes and pathways in the progression of hepatocellular carcinoma

Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma

Application of Microrna and Mrna Expression Profiling on Prognostic Biomarker Discovery for Hepatocellular Carcinoma

Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum

Bicluster and Pathway Enrichment Analysis Related to Tumor Progression of Hepatocellular Carcinoma

Study on the prediction model of liver cancer based on chronic liver disease and the related molecular mechanism

A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues